AN2 Therapeutics (ANTX) Director Readnour Sells Shares

What Happened

• Robin Shane Readnour, a member of AN2 Therapeutics' board, disposed of a total of 16,119 ANTX shares in open-market sales on Sept. 3 and Sept. 8, 2026, yielding approximately $97,323. Individual transactions: 2,877 shares @ $6.07 = $17,463; 3,223 shares @ $6.07 = $19,563; 4,725 shares @ $6.02 = $28,436; 5,294 shares @ $6.02 = $31,861.
• These were sales (code S) and were effected automatically pursuant to pre-established Rule 10b5-1 trading plans (see footnotes).

Key Details

• Transaction dates & prices: 2026-09-03 (2,877 @ $6.07; 3,223 @ $6.07) and 2026-09-08 (4,725 @ $6.02; 5,294 @ $6.02). Footnote indicates sale prices ranged $6.00–$6.085 (weighted average reported).
• Total shares sold: 16,119; total proceeds: ~$97,323.
• Sales were executed under Rule 10b5-1 plans adopted April 23, 2026 by MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP (F1, F2).
• Shares were held and sold by MGC-affiliated entities (MGC 2018 LP / MGC 2018 QP); Readnour is a member/managing partner of the general partner and disclaims beneficial ownership except for pecuniary interest (F4–F6).
• Filing: Form 4 filed Sept. 8, 2026 (covers trades on Sept. 3 and Sept. 8); filing date is within the expected reporting window for these transactions.

Context

• These were pre-planned, automated sales under 10b5-1 plans — such transactions are often routine and do not by themselves indicate a change in insider sentiment. The shares were sold by MGC-managed entities rather than directly by the individual.